Filing Flows › Companies › Ionis Pharmaceuticals › Timeline
Ionis Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−46.8% to $39.42
Ionis Pharmaceuticals (IONS) stock fell 47% over the last 252 sessions, to $39.42. On the way it reported 3 quarters, its insiders filed 5 open-market trades and 9 Form 144 notices of planned sales, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 16, 2026 | Form 144 | Form 144: Shannon L. Devers plans to sell $60K | −2.7% (−1.6% vs SPY) | −0.5% (+0.6% vs SPY) | — |
| Jul 31, 2026 | Insider buy | Hayden Michael R bought $258K | −2.9% (−3.6% vs SPY) | +2.2% (−1.3% vs SPY) | +13.6% (+9.9% vs SPY) |
| Jul 30, 2026 | Insider buy | Hayden Michael R bought $801K | −1.4% (−3.1% vs SPY) | +0.3% (−5.1% vs SPY) | +14.4% (+8.9% vs SPY) |
| Jul 29, 2026 | Earnings | Earnings: beat the EPS estimate by 51.7% | −2.3% (−0.8% vs SPY) | −0.4% (−4.5% vs SPY) | +13.6% (+10.2% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: C Frank Bennett plans to sell $5.7M | +3.7% (+4.2% vs SPY) | −38.2% (−37.9% vs SPY) | −41.2% (−43.9% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: Holly Kordasiewicz plans to sell $108K | +3.7% (+4.2% vs SPY) | −38.2% (−37.9% vs SPY) | −41.2% (−43.9% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: Allene M. Diaz plans to sell $864K | +3.7% (+4.2% vs SPY) | −38.2% (−37.9% vs SPY) | −41.2% (−43.9% vs SPY) |
| Jul 1, 2026 | Form 144 | Form 144: Joseph III Klein plans to sell $910K | −0.1% (0.0% vs SPY) | +6.3% (+6.5% vs SPY) | −39.8% (−39.1% vs SPY) |
| Jun 26, 2026 | Form 144 | Form 144: Eugene Schneider plans to sell $3.9M | +3.6% (+4.3% vs SPY) | +4.3% (+2.9% vs SPY) | −33.7% (−34.3% vs SPY) |
| Jun 26, 2026 | Form 144 | Form 144: Patrick R. O'Neil plans to sell $246K | +3.6% (+4.3% vs SPY) | +4.3% (+2.9% vs SPY) | −33.7% (−34.3% vs SPY) |
| Jun 26, 2026 | Form 144 | Form 144: Mariana Baroldi plans to sell $452K | +3.6% (+4.3% vs SPY) | +4.3% (+2.9% vs SPY) | −33.7% (−34.3% vs SPY) |
| Jun 25, 2026 | Form 144 | Form 144: Eric Swayze plans to sell $839K | +2.3% (+2.2% vs SPY) | +3.4% (+1.7% vs SPY) | −30.3% (−31.0% vs SPY) |
| Jun 8, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.3% (−1.5% vs SPY) | −1.6% (−2.2% vs SPY) | +12.6% (+11.3% vs SPY) |
| Apr 29, 2026 | Earnings | Earnings: beat the EPS estimate by 60.9% | +4.2% (+4.2% vs SPY) | +4.7% (+3.0% vs SPY) | +7.4% (+1.6% vs SPY) |
| Apr 16, 2026 | Insider sale | Jenne Kyle sold $368K | −2.1% (−2.3% vs SPY) | −2.6% (−4.2% vs SPY) | −1.5% (−8.2% vs SPY) |
| Apr 16, 2026 | Insider sale | Birchler Brian sold $73K | −2.1% (−2.3% vs SPY) | −2.6% (−4.2% vs SPY) | −1.5% (−8.2% vs SPY) |
| Apr 16, 2026 | Insider sale | Baroldi Joseph sold $419K | −2.1% (−2.3% vs SPY) | −2.6% (−4.2% vs SPY) | −1.5% (−8.2% vs SPY) |
| Mar 9, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.8% (+0.9% vs SPY) | −3.9% (−2.4% vs SPY) | −0.2% (+1.5% vs SPY) |
| Feb 25, 2026 | Earnings | Earnings: beat the EPS estimate by 5.6% | −5.4% (−6.3% vs SPY) | −8.3% (−7.3% vs SPY) | −16.2% (−11.9% vs SPY) |
| Nov 17, 2025 | 8-K | Material definitive agreement | +1.7% (+2.5% vs SPY) | +6.9% (+6.5% vs SPY) | +5.1% (+4.2% vs SPY) |
Insiders’ record here
In the year on the chart, Ionis Pharmaceuticals' insiders reported 2 open-market buys ($1.1M) and 3 sales ($860K). Of the 5 old enough to score, 3 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was −17.2% and after a sale −33.7%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Ionis Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.